Adrad Holdings Limited logo

Adrad Holdings Limited (AHL)

Market Closed
ASX ASX
54.88M Market Cap
4.24 P/E Ratio
- Div Yield
25,996 Volume
0 Eps
Want to track AHL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

AHL pays dividends to its shareholders, with the most recent payment made on Sep 29, 2025. The next estimated payment will be in 4 months ago on Mar 29, 2026 for a total of A$0.0208.
The last earnings report, released on Sep 02, 2025, exceeded the consensus estimates by 0%. On average, the company has fell short of earnings expectations by -0.0233%, based on the last three reports.
Adrad Holdings Limited has completed 2 stock splits, with the recent split occurring on Jul 10, 2015.
The company's stock is traded on one exchange.

Adrad Holdings Limited (AHL) FAQ

On which exchange is it traded?

Adrad Holdings Limited is listed on ASX.

What is its stock symbol?

The ticker symbol is AHL.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 54.88M.

Has Adrad Holdings Limited ever had a stock split?

Adrad Holdings Limited had 2 splits and the recent split was on Jul 10, 2015.

Adrad Holdings Limited Profile

Professional Services Industry
Industrials Sector
Engineer Mesha Rizal Sini CEO
ASX Exchange
AU000000AHL5 ISIN
ID Country
91 Employees
18 Mar 2026 Last Dividend
10 Jul 2015 Last Split
- IPO Date

Overview

PT Diagnos Laboratorium Utama Tbk is a prominent provider of health services through its network of laboratories across Indonesia. Established in 2007 with its headquarters in Jakarta Pusat, Indonesia, the company has been at the forefront of delivering comprehensive laboratory testing and health services to meet various patient needs. By harnessing advanced diagnostic technologies and expertise, PT Diagnos Laboratorium Utama Tbk plays a critical role in the early detection, diagnosis, and management of diseases, contributing significantly to the health and well-being of Indonesian communities.

Products and Services

Clinical Pathology Laboratory Tests: The company provides a wide range of clinical pathology services, including:

  • Hematology: Analysis of blood cells to diagnose blood disorders and hematological conditions.
  • Hemostasis: Assessment of blood clotting mechanisms, crucial for diagnosing bleeding disorders.
  • Clinical Chemistry: Measurement of chemical substances in the body fluids, instrumental in diagnosing various diseases.
  • Urinalysis: Examination of urine for disease markers, including those for kidney disease.
  • Biomolecular: Testing at the molecular level to identify genetic markers and mutations.
  • Immunology: Evaluation of the immune system’s functioning, including autoimmune diseases and allergies.
  • Microbiology: Identification of bacterial, viral, and other microbial infections.
  • Anatomical Pathology: Examination of body tissue samples to diagnose diseases and conditions.

Genomics Laboratory Tests: Specializes in genetic testing across various applications, such as:

  • Reproductive Health: Offering genetic insights for individuals planning for a family.
  • Pregnant Women: Genetic screenings for expectant mothers to detect potential health concerns.
  • Oncology Tests: Identifying genetic markers associated with cancer to tailor treatment plans.
  • Drug Sensitivity: Analyzing genetic factors that influence response to medications.
  • DNAandMe: Personalized genetic testing for insights into ancestry and predisposition to certain health conditions.

Homecare Health Services: Bringing laboratory testing services directly to the patient’s home, offering convenience and privacy. Services include:

  • Tests for hemoglobin, ferritin, reticulosit, and routine hematology.
  • SARS-COV-2 omicron screening molecular test, and PCR SARS-COV-2 tests conducted in the comfort of the patient’s home.

SARS-CoV-2 Screening Services: Offering comprehensive screening services for COVID-19, including tests for the omicron variant, to support public health efforts in managing the pandemic.

Contact Information

Address: Gedung Graha Anam Lantai 2, Jakarta Pusat, Indonesia, 10350
Phone: 62 21 3193 1833